Vaxil was founded by Weizmann Institute scientists, Israel's top research university, in order to provide an altogether novel approach to immunotherapy. Vaxil has diligently advanced its immunotherapy platform and published its research and clinical results in top medical journals.
Immunotherapy has become the most promising field in the fight against cancer. Whereas chemotherapy was once seen as a breakthrough and still utilized successfully in many patients, today’s scientists recognize immunotherapy is the way of the future. Learn More
VAXIL’S PRIMARY PLATFORM GENERATES COMPREHENSIVE IDENTIFICATION, ISOLATION & PRODUCTION OF ANTIGEN-SPECIFIC IMMUNOTHERAPIES Vaxil’s VaxHit™ platform technology combines proprietary algorithms which enable in-silico identification of signal peptides domains and their subsequent use as immunotherapeutic products. The VaxHit™ platform is essentially a launchpad for novel and uniquely targeted immunotherapy products.
Vaxil's team includes executives and scientists with deep industry experience in Israel, the US, and Canada. Supporting Vaxil's immunotherapy platform development are six specialized PhD scientists.